• Y-27632 Dihydrochloride: ROCK Inhibitor Workflows

  2026-08-17

  Y-27632 dihydrochloride provides a selective way to connect Rho–ROCK signaling with cytoskeletal remodeling, cell survival, and invasion phenotypes. This workflow-focused guide shows how to use it as a controlled perturbation in stem-cell, neuronal, smooth-muscle, and cancer research while avoiding dose, timing, and interpretation errors.

• Optimizing hiPSC-Derived Functional Platelet Production

  2026-08-17

  A 2026 study developed an optimized differentiation scheme that increases megakaryocyte and platelet output from human induced pluripotent stem cells while shortening production time and lowering costs. Its combination of higher embryoid body input, human platelet lysate, cytokine-replacing small molecules, and maturation-promoting compounds provides a practical framework for more scalable platelet manufacturing research.

• Neomycin Sulfate: Mechanisms and Research Use

  2026-08-16

  Neomycin sulfate is an aminoglycoside antibiotic used as a molecular probe for RNA/DNA structure interaction studies and ion-channel research. Its documented actions include stabilizing hammerhead ribozyme ground-state complexes, disrupting HIV-1 Tat–TAR recognition, stabilizing DNA triplexes, and blocking ryanodine receptor channels.

• NADH/NAD+ Redox Imbalance in Diabetic Kidney Disease

  2026-08-15

  Yan’s 2021 review identifies NADH/NAD+ redox imbalance, oxidative stress, and mitochondrial dysfunction as interconnected drivers of diabetic kidney disease. Its main contribution is a pathway-based framework linking excess NADH production and reduced NAD+ availability to impaired mitochondrial homeostasis, while highlighting intervention strategies that require further validation.

• SmD2 Acetylation and PARP Inhibitor Sensitivity in HCC

  2026-08-14

  This study identifies the spliceosome core protein SmD2 as an acetylation-sensitive regulator of BRCA1/FANC cassette exons, DNA repair, and PARP inhibitor response in hepatocellular carcinoma. Its findings support a preclinical strategy combining HDAC2-directed spliceosome regulation with PARP inhibition to expose DNA repair vulnerabilities in BRCA-proficient HCC.

• Calpain Inhibitor I, ALLN: Practical Lab Guide

  2026-08-14

  Calpain Inhibitor I, ALLN (SKU A2602) is a cysteine-protease inhibitor for workflows examining calpain and cathepsin contributions to apoptosis, inflammation, and ischemia-reperfusion injury. It is intended for research use with matched vehicle controls and orthogonal readouts, not for diagnostic, therapeutic, or single-protease-specific applications.

• ATRA Restores Niraparib Sensitivity After Cisplatin

  2026-08-13

  Mei and colleagues show that all-trans retinoic acid (ATRA) can reduce cisplatin-induced resistance to Niraparib in epithelial ovarian cancer models. The work identifies a resistance-associated program involving ALDH1A1, NAMPT, PARP1, CHK1, and intracellular NAD+, supporting sequential cisplatin, ATRA, and PARP-inhibitor maintenance as a mechanistically informed strategy.

• Cyclophosphamide Workflows for Cancer Research

  2026-08-13

  Build reproducible Cyclophosphamide workflows for apoptosis assays, immune-modulation studies, and transplantation models. This guide combines formulation controls, schedule-aware experimental design, and troubleshooting strategies for APExBIO’s validated alkylating chemotherapeutic agent.

• Danazol and Precocious Puberty Model Logic

  2026-08-12

  Danazol provides a distinctive endocrine perturbation model that connects androgen receptor signaling, steroidogenesis, and hypothalamic–pituitary–gonadal activity. This article interprets the 2025 rat study on herbal prevention through assay design, mechanistic boundaries, and translational relevance.

• Angiotensin Peptides and SARS-CoV-2 Receptor Binding

  2026-08-12

  The 2025 study shows that naturally occurring angiotensin fragments can alter SARS-CoV-2 spike binding in a receptor-selective and sequence-dependent manner, identifying a mechanistic connection between the renin-angiotensin system and viral entry biology. Its comparison of intact, truncated, and chemically modified peptides provides a useful framework for studying Angiotensin 1/2 (1-6) in receptor-binding assays while emphasizing that enhanced binding is not equivalent to increased infection or clinical risk.

• Vitamin C: Redox-Aware Assay Design

  2026-08-11

  Vitamin C and ascorbic acid can produce context-dependent redox, senescence, and anticancer phenotypes. This guide translates recent ROS/NF-κB findings into practical assay decisions for reproducible cell-based cancer research.

• Rucaparib for Reliable DNA Repair Assays

  2026-08-11

  This scenario-driven guide explains how Rucaparib (AG-014699, PF-01367338), SKU A8893, can support reproducible viability, DNA-damage, and radiosensitization studies. It covers assay compatibility, DMSO handling, protocol design, transporter-aware interpretation, and evidence-based product selection.

• Dutasteride Workflows for Prostate Research

  2026-08-10

  Build reproducible prostate cancer and BPH research workflows around Dutasteride, from DHT-conversion assays to apoptosis validation. Practical formulation guidance, orthogonal readouts, and a carefully bounded comparison with liver ischemia–reperfusion research help researchers distinguish mechanism from phenotype.

• Abiraterone acetate in 3D Prostate Cancer Models

  2026-08-09

  Use Abiraterone acetate as a mechanistically defined CYP17 inhibitor in patient-derived spheroids, while separating steroidogenesis effects from direct viability changes. This workflow combines controlled dosing, orthogonal readouts, and reference-informed troubleshooting for translational prostate cancer research.

• Alfuzosin HCl: From Signal to Assay

  2026-08-08

  Alfuzosin HCl connects α1-receptor pharmacology with practical assay design for benign prostatic hyperplasia research. This guide shows how spectrofluorometric evidence, formulation variables, and functional endpoints can be integrated without overstating translational conclusions.

16453 records 1/1097 page Next 12345 下5页 Last page